JW Pharmaceutical Corporation (KRX:001060)
South Korea · Delayed Price · Currency is KRW | Market Cap | 647.71B +26.9% |
| Revenue (ttm) | 775.30B +7.8% |
| Net Income | 60.65B -5.4% |
| EPS | 2,676.46 +1.2% |
| Shares Out | 22.89M |
| PE Ratio | 10.59 |
| Forward PE | n/a |
| Dividend | 650.00 (2.20%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 37,604 |
| Average Volume | 74,407 |
| Open | 28,550 |
| Previous Close | 28,350 |
| Day's Range | 28,550 - 29,200 |
| 52-Week Range | 20,700 - 39,250 |
| Beta | 1.06 |
| RSI | 38.55 |
| Earnings Date | May 21, 2026 |
About JW Pharmaceutical
JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea. [Read more]
Financial Performance
In 2025, JW Pharmaceutical's revenue was 775.30 billion, an increase of 7.77% compared to the previous year's 719.38 billion. Earnings were 60.65 billion, a decrease of -6.75%.
Financial StatementsNews
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
BEIJING and BRIDGEWATER, N.J. , April 9, 2026 /CNW/ -- Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW...